Potential of regulatory T-cell-based therapies in the management of severe COVID-19
Emmanuel Stephen‐Victor, Mrinmoy Das, Anupama Karnam, Bruno Pitard, Jean–François Gautier, Jagadeesh Bayry
Abstract
<b>In view of dysregulated immune response, “cytokine storm” and inflammation-induced lung damage in severely ill COVID-19 patients, we propose that CD4<sup>+</sup>CD25<sup>+</sup>FoxP3<sup>+</sup> regulatory T-cell-based therapies could be considered for patient management</b>https://bit.ly/3eKqWPo
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)Cytokine stormFOXP3Immune systemInflammation2019-20 coronavirus outbreakCytokineIL-2 receptorSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Regulatory T cellImmunologyT cellVirologyInternal medicineDiseaseOutbreakInfectious disease (medical specialty)COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19